ERBB2 and head and neck squamous cell carcinoma: Another open field of research is based on the evidence that non-canonical ErbB signaling mechanisms are involved in HNSCC progression and resistance to therapy, which may lead to the development of therapeutic agents aimed at targeting EGFR nuclear translocation or EGFR/ErbB2 exosomal transfer.